6 pharmaceutical companies disclosed three quarterly report forecasts, all of which were expected to be happy!

【Pharmaceutical Network Industry News】Recently, listed companies in the A-share market have successively released third-quarter performance forecasts
.

According to incomplete statistics, as of now, 6 A-share companies in the field of medicine and biology have disclosed three quarterly report forecasts, and their performance is pre-gratifying
.

Kelun Pharmaceutical: Net profit increased by 55%-70% year-on-year On the evening of September 15, Kelun Pharmaceutical, a large infusion head company, disclosed its performance forecast, and it is expected that the net profit in the first three quarters will be 1.
315 billion yuan - 1.
442 billion yuan, an increase of 55% -70%
year-on-year.

The reasons for the change in performance include: the company is fully expanding the market for infusion and non-infusion products, continuously optimizing the product structure, increasing the sales of newly approved products, and increasing profits year-on-year; The market price of the main products of Yili Chuanning Biotechnology Co.
, Ltd.
, a holding subsidiary of the company, increased, and the profit increased year-on-year; In addition, the company's innovative R&D project A (SKB264/MK-2870) and MSD reached a cooperation agreement and a paid exclusive license, which increased revenue and profits during the reporting period in accordance with the contractual obligations of the holding subsidiary Colombotai; Colombotai has exclusively licensed its proprietary clinical early-stage biomacromolecule tumor project B with independent intellectual property rights to MSD for research, development, manufacturing and commercialization
worldwide.

Kaipu Biologics: Net profit increased by 108.
68% -124.
14% year-on-year On September 19, Kaipu Biologics, a domestic nucleic acid molecular diagnostic products and service provider, released the first three quarters of 2022 performance forecast, during the reporting period, the net profit attributable to the shareholders of listed companies is expected to make a profit of 1.
35 billion yuan - 1.
45 billion yuan, an increase of 108.
68% -124.
14%
over the same period last year.

For the reasons for the growth in performance, the company said that during the reporting period, the company continued to promote the integrated business model of "nucleic acid detection products + medical testing services", actively exerted the company's product technology and market advantages, and strengthened market expansion
.

During the reporting period, due to the increase in demand for nucleic acid testing, the company's sampling consumables, nucleic acid extraction reagents, etc.
brought sales pull, related business achieved rapid development
.

Zuoli Pharmaceutical: Net profit increased by 52.
07% -59.
67% year-on-year On August 29, Zuoli Pharmaceutical released the first three quarters of 2022 performance forecast in the evening, and it is expected to achieve a net profit attributable to the mother of 200 million yuan – 210 million yuan, an increase of 52.
07% -59.
67%
year-on-year.

The reason for the growth in performance is that the sales revenue of the company's core products, Wuling capsules and Lingze tablets, has increased significantly compared with the same period last year; At the same time, Chinese medicine tablets and formula granules continued to strengthen business expansion, and sales revenue increased better than the same period last year; Affected by the Hubei Alliance collection, the sales of 100 orders in the third quarter have been affected
.

Opram: Net profit is expected to grow capped at 80% Opram listed on September 2, 2022, expects revenue and net profit to continue its growth trend in the third quarter, with net profit expected to grow capped at 80%
in the first three quarters.

It is reported that Opmey is the first listed company to take the sales of cell culture media products as the main source of income, and its main business involves the development and production of
cell culture media and biopharmaceutical commissions.

Micro electrophysiology: net profit increased by 45.
48% to 81.
83% year-on-year The micro-electrophysiology recently launched on the Science and Technology Innovation Board is expected to increase revenue by 31.
05% to 45.
61% year-on-year in the third quarter of 2022, net profit increased by 45.
48% to 81.
83% year-on-year, and deducted non-net profit increased by 53.
64% to 67.
91%
year-on-year.

According to the data, microelectrophysiology is an enterprise focusing on the research and development, production and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and treatment and ablative therapy, and is committed to providing a globally competitive "integrated solution for diagnosis and ablation therapy with accurate interventional navigation as the core"
.

BGI Intelligent Manufacturing: Net profit increased by 15.
26%-20.
88% year-on-year Huada Intelligent Manufacturing that landed on the A-share capital market on September 9 expects to achieve operating income of about 3.
281 billion to 3.
441 billion yuan in the first three quarters of this year, an increase of 15.
26% to 20.
88% year-on-year; It is expected to achieve attributable net profit of approximately 1.
893 billion to 2.
023 billion yuan, an increase of 311.
8% to 340.
08%
year-on-year.

BGI Intelligent Manufacturing focuses on the field of life science and biotechnology, with the research and development, production and sales of related products such as instruments and equipment, reagents and consumables as its main business, and its main products and services cover three major sectors
: gene sequencer business, laboratory automation business and new business.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.